Revolution Medicines Seeks H1 2026 Pancreatic Cancer Trial Readout, Expands to Eight Phase 3 Studies
Revolution Medicines expects a pivotal RASolute 302 Phase 3 readout of daraxonrasib in second-line metastatic pancreatic cancer in H1 2026 and plans three additional Phase 3 trial starts, expanding its late-stage pipeline to eight studies. It forecasts NSCLC enrollment completion in 2026 and initiated RASolute 305 for first-line G12D-mutant PDAC.
1. Financial Results and Corporate Update
Revolution Medicines reported its fourth quarter and full year 2025 financial results, reaffirming a strong cash runway to support ongoing RAS-targeted oncology programs. The update emphasized continued investment in late-stage clinical development and preparation for multiple upcoming data readouts.
2. Pancreatic Cancer Phase 3 Program
Global enrollment for RASolute 302, a registrational Phase 3 trial of daraxonrasib in second-line metastatic pancreatic ductal adenocarcinoma, is complete with results expected in the first half of 2026. The company also initiated RASolute 305 evaluating zoldonrasib in first-line G12D-mutant PDAC and plans to launch RASolute 303 and 304 later this year.
3. NSCLC Development and Future Trials
In non-small cell lung cancer, enrollment in the RASolve 301 Phase 3 trial of daraxonrasib in previously treated patients is set to substantially complete in 2026. Additionally, the company is preparing to start RASolve 308, a placebo-controlled Phase 3 study of zoldonrasib in first-line RAS G12D metastatic NSCLC, in the first half of 2026.